RxDoctor Payments Data

James Chun, MD

Cardiovascular Disease · San Francisco, CANPI 1134143506

Payments from drug & device makers

$8,804in general payments, 2019–2025

Across 108 payments — averaging $81.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$4K
  • Sanofi-aventis U.S. LLC$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$318
  • Amgen$308
  • GE HealthCare$275
  • Bardy Diagnostics, Inc.$273
  • plus $1K from 20 others

What the payments were for

  • Consulting fees$3674%
  • Speaking & faculty fees$5,23859%
  • Travel & lodging$6437%
  • Food & beverage$2,55629%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,804 in reported general payments places this provider in the 70th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$192,977
Medicare patients
372
Services billed
1,333

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban231$326,921
XareltoRivaroxaban187$268,988
EntrestoSacubitril/Valsartan59$81,578
MultaqDronedarone Hcl32$61,554
JardianceEmpagliflozin28$44,299
FarxigaDapagliflozin Propanediol30$40,172
BrilintaTicagrelor15$16,556
Amiodarone Hcl77$4,103
Metoprolol Succinate290$3,932
Ezetimibe127$3,076
Atorvastatin Calcium324$2,770
Rosuvastatin Calcium98$2,311
Labetalol Hcl24$1,865
ClopidogrelClopidogrel Bisulfate123$1,498
Losartan Potassium148$1,191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$53$326,921231 claims
Johnson & JohnsonXarelto$84$268,988187 claims
NovartisEntresto$79$81,57859 claims
Sanofi-aventis U.S. LLCMultaq$2,200$61,55432 claims
AstraZenecaFarxiga, Brilinta$52$56,72845 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →